On this episode we speak with Leah. Leah is a research assistant at Trialnet.org. but is also an MPH candidate in Epidemiology. Her drive comes from her family and friends.  She's seen T1D up close and is passionate about early detection and making research feel human, accessible, and community powered. Her allyship speaks volumes!

At Trialnet they test family members of people living with T1D for risks of being diagnosed. They start testing as young as the age of 2 for T1D autoantibodies, all the way up to the

age of 40 if you have direct family members with T1D.

Trial Net contributed greatly to the treatment of Teplizomab, Tzield® (teplizumab) which is s a CD3-directed monoclonal antibody approved for delaying the onset of stage 3 type 1 diabetes in adults and children aged 8 years and older who have Stage 2 type 1 diabetes. It works by attaching to proteins on immune cells, helping to protect the insulin-producing cells in the pancreas from being attacked. Tzield was approved in the US in November 2022 and is the first

disease-modifying therapy for autoimmune type 1 diabetes.

For more detailed information, you can refer to the official Tzield website or the FDA label

During our conversation we speak about the misdiagnosis of adults with diabetes and the challenges in care because of the proper education and tools not being given to them. At Trial Net, instead of continuously monitoring a finger pricks, that we know the child hates, and parents hate as well, if you live with T1Dyou can just have this simple lab drawn to determine their future risks. It's a win-win for everyone! It's a simple blood withdrawal; it's not a lot. It's no more than a typical blood withdrawal from a lab. If they can get this done, you will have immediate direct knowledge of what to look for moving forward. Is my child going to have it or if

they're not? Right.

Visit Trialnet.org to get screened. It's 100% Free.